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Background: South Africa is a major hub of HIV prevention trials, with plans for a licensure trial to start in 2015.
The appropriate standards of care and of prevention in HIV vaccine trials are complex and debated issues and
ethical guidelines offer some direction. However, there has been limited empirical exploration of South African
stakeholders’ perspectives on ethical guidance related to prevention and care in HIV vaccine trials.
Methods: Site staff, Community Advisory Board members and Research Ethics Committee members involved with
current HIV vaccine trials in South Africa were invited to participate in an exploration of their views. A questionnaire
listed 10 care and 10 prevention recommendations drawn from two widely available sets of ethical guidelines for
biomedical HIV prevention trials. Respondents (n = 98) rated each recommendation on five dimensions: “Familiarity
with”, “Ease of Understanding”, “Ease of Implementing”, “Perceived Protection”, and “Agreement with” each
ethical recommendation. The ratings were used to describe stakeholder perspectives on dimensions for each
recommendation. Dimension ratings were averaged across the five dimensions and used as an indication of
overall merit for each recommendation. Differences were explored across dimensions, between care-oriented
and prevention-oriented recommendations, and between stakeholder groups.
Results: Both care and prevention recommendations were rated highly overall, with median ratings well above
the scale midpoint. In general, informed consent recommendations were most positively rated. Care-related
recommendations were rated significantly more positively than prevention-related recommendations, with the
five lowest-rated recommendations being prevention-related. The most problematic dimension across all
recommendations was “Ease of Implementing,” and the least problematic was “Agreement with,” suggesting the
most pressing stakeholder concerns are practical rather than theoretical; that is, respondents agree with but see
barriers to the attainment of these recommendations.
Conclusions: We propose that prevention recommendations be prioritized for refinement, especially those
assigned bottom-ranking scores for “Ease of Implementing”, and/ or “Ease of Understanding” in order to assist vaccine
stakeholders to better comprehend and implement these recommendations. Further qualitative research could also
assist to better understand nuances in stakeholder reservations about implementing such recommendations.Background
South Africa has identified the development of safe and
effective HIV vaccines as a health priority [1,2]. The coun-
try has developed national standards on ethics for HIV
vaccine research, namely the Medical Research Council of
South Africa’s Guidelines on Ethics for Medical Research:
HIV preventive vaccine trials [1], and domestic vaccine
stakeholders are also governed by international guidelines* Correspondence: rmoorhouse@ohri.ca
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article, unless otherwise stated.on ethics for HIV prevention trials [3,4]. To-date however
there has been limited empirical exploration on whether
current normative guidance is perceived to offer sound
direction about current ethical complexities in HIV vaccine
trials (HVTs).
In 2011 there were 5.6 million South Africans living
with HIV [5]. While South Africa now runs a large anti-
retroviral therapy (ART) treatment program, the number
of ART-eligible South Africans continues to exceed
coverage [6]. Research into new prevention technologies
and methods is vitally important in the battle against
the epidemic. To this end, South Africa has conductedtral Ltd. This is an Open Access article distributed under the terms of the
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rently implementing preventive HVT protocols, however,
a massive scale up of site capacity is expected as South
Africa prepares to implement a phase III licensure trial in
the country in approximately 2015.
In South Africa and other host countries for HVTs,
participants are often drawn from communities with
relatively poor socio-economic conditions and strained
health-care resources yet funded by agencies from re-
sourced nations [7,8]. These imbalances frame intense
ethical debate regarding sponsor-investigator obligations
vis-à-vis the rights and wellbeing of participants and par-
ticipating communities. Two related and divisive ethical
debates in HVTs are the responsibilities of sponsor-
investigators to offer a high standard of HIV prevention
and to take steps to address the medical needs identified
in trials, including HIV.
Individuals are deemed eligible for late-phase HVTs
because they are at high risk of HIV infection. Many
commentators have deliberated on the responsibilities of
sponsor-investigators to ensure that such participants
receive access to effective methods to prevent HIV acqui-
sition and how such decisions should be made, parti-
cularly where such methods are not routinely available
[9-12]. Considerations include defining when scientific
thresholds have been met for ‘proving’ the effectiveness of
prevention methods [13], obtaining the ‘approval’ of rele-
vant authorities for such methods, and getting stakeholder
agreement which may require overcoming possible cul-
tural objections to these prevention methods [14]. Some
debated concerns include the possible biological and
behavioural interactions between prevention methods
[15], determining how much risk reduction methods
will decrease expected sero-incidence rates and affect
study power [10,16-18], the impact on product licensure
[15,19] and the role tension between promoting risk-
reduction and promoting scientific objectives [3].
Some participants in HVTs will acquire HIV infection
despite access to a range of effective HIV prevention
methods. In addition, other health-care problems are
likely to be identified by site staff [20,21]. There has been
intense discussion about the obligations of sponsor-
investigators to address the HIV-related needs of partici-
pants, particularly in settings where access to comprehensive
care and ART is not reliably available [22-24]. The discussion
has also expanded to include actions researchers
should take to address medical problems apart from
HIV infection, and obligations to build local capacity
for health care [25,26].
Debates have centred on the ethical justification
underpinning the responsibility to address participants'
medical problems by sponsor-investigators [23,24] and
identifying reasonable limits on such responsibilities
[27]. Some commentators maintain that a high standardof care for HVT participants may introduce unacceptable
local inequalities or constitute an ‘undue inducement’
[28]. General ethical guidelines do not provide complete
answers to these complex questions surrounding preven-
tion and care in HVTs. However, international documents
do offer certain recommendations. Trial stakeholders in
South Africa can also turn to domestic guidance adapted
from the UNAIDS (2000) guidelines [1].
While defining ethical norms in HIV prevention research
is complex, determining the process by which ethical
standards are to be established can be an equal challenge.
One such complexity is the role of consultation in
guideline-development. When UNAIDS released its Ethical
Considerations in HIV Preventive Vaccine Research guide-
lines (2000) [29] some commentators argued the guidelines
did not represent international agreement; but rather
reflected the opinions of the small group of drafters [30].
This contention highlights stakeholder interest in just and
participatory methods for determining guideline content.
Other complexities include whether guidelines should
be aspirational or mandatory. Should they represent
ideals to strive for without threat of retribution (so called
aspirational guidance) or rather represent a basis for sanc-
tion (mandatory guidance) [31]? Should guidelines present
a substantive position or a decision-making standard for
resolution of divisive issues [7]? In addition, it has been
noted that a guideline’s formal purpose (e.g. aspirational,
regulatory, or educational) may or may not correspond
with the intended audience’s reading of the guideline [32].
Commentators have noted that guidelines can be extolled
and ‘exhibited in practice’ (functional norms) or extolled
but ‘ignored’ (non-functional norms) [33]. If guidelines are
ignored, there are conceivably various reasons for that:
there could be low awareness of the recommendation; it
could be phrased poorly or ambiguously; or it could be
considered unachievable or irrelevant to local context by
the intended audience. Learning more about stakeholder
perspectives of ethical guidelines might, therefore, assist
to improve their status as functional norms. The latter
observation intersects with a broader debate about the
role of empirical data in bioethics [34-37]. Sugarman and
Sulmasy [38] propose several roles for empirical research
in bioethics including describing facts relevant to norma-
tive arguments. As set out in Slack [39], empirical research
can inform a critical reflection on ethical norms [34] by,
for example, shedding light on ethical problems that
require attention [40] or by providing the details that
inform more responsive ethical recommendations [41].
This empirical study describes stakeholder perspectives
regarding key guidance to aid in creating guidance
that is more responsive to these perspectives and to
the implied needs of guidance users.
While debate continues on the appropriate relation-
ship between empirical and conceptual modes of inquiry,
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and do contribute to the discourse on normative ethics.
In the Global South, there has been some empirical
research focused on the ethical perspectives of
research stakeholders [28,42-44] and explorations of
perceived challenges by HVT stakeholders in South Africa
[45,46]. The UNAIDS-AVAC Good Participatory Practice
Guidelines for Biomedical HIV Prevention Trials guide-
lines (2007) (GPP guidelines) [4] have been evaluated to
establish stakeholder awareness and utilization [47] and to
gauge stakeholder perceptions of their relevance [48].
Additionally, empirical explorations of care and preven-
tion practices in HIV prevention trials have been under-
taken but did not specifically focus on perceptions of
guidance [21,49,50]. We undertook a descriptive ethics
study to fill this gap and focus on two sets of international
ethical guidelines: Ethical considerations in biomedical
HIV prevention trials (2007) (UNAIDS guidelines) [3]
and the GPP guidelines [4].
The UNAIDS guidelines are framed as ‘suggested
guidance’ and the GPP guidelines are intended to act
as systematic guidance regarding engagement in trials.
Some commentators have discussed the possibility that
UNAIDS guidance documents set an unpragmatic standard
for research stakeholders [28,31]. Although the UNAIDS
guidelines and recent revisions to both booklets [51,52]
have been available for some time, there has been little
empirical exploration of the guidance, including whether
stakeholders are aware of their recommendations or
whether they think the recommendations offer helpful
direction on key concerns.
Study aims
This study aimed to explore South African stakeholder
perspectives of ethical recommendations for the complex
and controversial issues of prevention and care in HVTs.
We sought to identify where ‘functionality’ of these ethical
recommendations could be improved. Vaccine stake-
holders are the primary audience for our study, including
guideline-developers. As such, we conclude with sug-
gested reforms to improve the guidelines and make them
more responsive to stakeholder perceptions about their
usefulness. The study’s findings, however, may also be of
interest to a broader readership concerned with the role of
empirical data in contributing to the refinement of ethical
norms and recommendations.
The three questions driving this specific study were: 1)
which overall ethical recommendations are perceived
most and least favourably (on the dimensions of fami-
liarity with, ease of understanding, ease of implementing,
perceived protection, and agreement with); 2) whether
stakeholders perceive care-related recommendations to
be more or less challenging than prevention-related rec-
ommendations; and 3) whether differences exist betweenstakeholder groups regarding their views on ethical
recommendations. This study was part of a larger qualita-
tive exploration of care and prevention practices of HVT
stakeholders, funded by the Wellcome Trust’s Biomedical
Ethics Program.
Methods
Our exploratory inquiry used a quantitative survey
design, as this design is well suited to describing know-
ledge, beliefs and attitudes [38]. The survey allowed us
to sample a large number of respondents within a rela-
tively short data collection period and to make compari-
sons across stakeholder groups, which was a priority for
analysis. There were a limited number of open-ended
items included in the questionnaire, however, in the
interests of space this data is not reported here.
Instrument development
The study team identified 20 key ethical recommendations
from the UNAIDS guidelines and GPP guidelines that
provided direction regarding prevention and care services
that should be made available to participants in HVT, how
such services should be ensured, or how decisions on
care and prevention should be made. Recommenda-
tions were selected for inclusion in the questionnaire
if they were relevant to the complex, unresolved and
topical care and prevention issues being debated in
ethics discourse [15,19,27,50].
A questionnaire was developed to allow respondents to
evaluate each ethical recommendation with Likert-type
ratings on various dimensions (see Additional file 1). These
dimensions were “Familiarity with”, “Ease of Understanding”,
“Ease of Implementing”, “Perceived Protection”, and
“Agreement with” the recommendation. Averaged ratings
across these dimensions for each recommendation were
taken as scales indicating the recommendation's overall
perceived merit. Summaries for each dimension and over-
all merit were calculated to compare overall perceptions
of care- and prevention-oriented recommendations.
The questionnaire was piloted with a small ethically
knowledgeable sample (n = 20). Sixteen individuals reviewed
the items (for relevance to study objectives, clarity, and
questionnaire structure) and eleven completed the question-
naire. Of these pilot respondents, seven both reviewed the
items and completed the questionnaire. Poor items were
revised or discarded when preliminary item analysis indi-
cated they were too ambiguous or otherwise unsuitable
for inclusion. All materials were developed in English and
translated on request.
Sampling
Three key stakeholder groups were selected for partici-
pation: current trial site-staff involved in HVT implemen-
tation at five sites conducting HVTs, current members on
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and Research Ethics Committee (REC) members on RECs
known to have reviewed current HVTs in South Africa.
The Principal Investigators at each HVT site agreed to
sensitization meetings with site-staff and CABs to dis-
cuss participation and, with their approval, provided full
lists of eligible site-staff and CAB members for sampling.
Chairs of eligible RECs were approached via email to
negotiate access and all were willing to provide full
membership lists except one REC, which sent a shorter
list of members willing to be approached. Since the
pool of eligible participants was small, sampling was
exhaustive rather than random.
Data collection
Data collection was conducted between June 2010 and
July 2011. Standard Operating Procedures were developed
for the collection of questionnaire data, anonymisation,
documentation, and data integrity and security. When
stakeholders first responded, an information sheet inclu-
ding an informed consent form was provided digitally.
Typically trial site staff and RECs responded by email,
while CAB members participated at a CAB meeting.
Participants received a modest reimbursement for their
time and inconvenience, approved by local RECs.
Data analysis
The Likert-type dimension ratings for the list of ethical rec-
ommendations were designed to form multi-item measures
as follows: (1) Summary scales representing perceived over-
all merit of each ethical recommendation, (2) Summary
scales representing perceived overall merit for care recom-
mendations combined and prevention recommendations
combined, and (3) Summary scales for each dimension
across care recommendations combined and across
prevention recommendations combined. In each case
reliability was assessed with Cronbach’s Alpha to justify
scaling items along these lines. Summary scale scores were
tabulated and interpreted as more or less ‘problematic’ or
having more or less ‘merit’ depending on their relative
ranking. These evaluations did not challenge the absolute
merit of the recommendations; rather, a more ‘problematic’
recommendation was identified as one where its perceived
merit was lower relative to other recommendations.
Scores were calculated as follows: (1) Since scores for
each dimension of a single recommendation ranged from
1 to 5, a global merit score for each recommendation was
added up by combining the five individual dimension
scores for that recommendation. Each recommendation
thereby received a single summated score ranging from a
possible 5 to 25; (2) Since the overall merit score for each
ethical recommendation ranged from a possible 5 to 25,
overall merit scores for the 10 care recommendations
combined added up to a summated score ranging from apossible 50 to 250; the same summation was done for the
10 prevention recommendations combined; (3) Scores for
each dimension of every individual recommendation were
then summated again; instead of adding dimension scores
together within a single recommendation, this summation
added up all individual “Familiarity with” dimension items
for care recommendations. As there were ten care recom-
mendations, there were ten scores that were summated
into one combined score for care recommendations ran-
ging from a possible 10 to 50 for the “Familiarity with”
dimension. The same process was repeated for the other
dimensions, yielding five combined dimension scores for
care recommendations. The same five combined dimension
scores were calculated for prevention recommendations.
For (1), perceived global merit of each ethical recom-
mendation, a z-score was calculated for the merit rating
of each ethical recommendation to more accurately
compare scales with different levels of variability. This
was particularly important because ratings of some recom-
mendations had very little variability while others exhibited
a great deal. These standardized scores for recommenda-
tions were then ranked from 1 (the highest scoring recom-
mendation) to 20 (the lowest scoring recommendation). A
z-score was also calculated and ranked for each recom-
mendation's five individual dimensions. Since there were
20 recommendations that were each scored on five dimen-
sions, there were 100 scores in total from 1 (the highest
scoring recommendation-dimension score) to 100 (the
lowest scoring recommendation-dimension score).
For (2) and (3), global and dimension-specific merit
of care recommendations combined versus prevention
recommendations combined, paired t-tests were used
to determine whether differences in median scores were
significant. Median and interquartile range (IQR) were de-
termined for responses ‘overall’ and by stakeholder group.
A Kruskal-Wallis (KW) test was conducted to explore dif-
ferences in dimension-specific perceptions of care versus
prevention recommendations across stakeholder groups.
The KW test was selected because it is non-parametric
and does not require that sample data are even or distri-
buted normally, and we anticipated small uneven sample
sizes given the small uneven sized populations from which
the study would sample. To offset family-wise error, a
conservative Bonferoni correction set alpha at 0.003 for
paired t-tests and KW tests. All quantitative analyses were
performed in Statistical Analysis System software.
Ethical considerations
Ethics approval was obtained for this study from the
University of Kwazulu-Natal Biomedical Research Ethics
Committee (BE 241/09) and from Simon Fraser University's
Research Ethics Board. Ethical approval was also obtained
from all Research Ethics Committees with jurisdiction over
the HVT sites at which data was collected.
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A total of 98 questionnaires were completed (69 from
CABs, 21 from RECs, and 8 from site staff) with a response
rate of 43%. Internal consistency for global merit scores
was >0.6 in all cases for each recommendation statement,
when recommendations were summarized by category (i.e.
prevention recommendations combined and care recom-
mendations combined), and for the global merit scores for
care and prevention combined (i.e. combining “Familiarity
with”, “Ease of Understanding”, “Ease of Implementing”,
“Perceived Protection”, and “Agreement with” across all
care recommendations and the same across all prevention
recommendations). This item analysis indicates that
all scales had sufficient reliability for the purposes of
this study.
Ethical recommendations
The first question driving this study was which overall
ethical recommendations are perceived as having more
or less merit (or, which recommendations are perceived
as more or less challenging by stakeholders)? Figure 1
presents all ethical recommendations in order from top
overall merit rank to bottom overall merit rank. The
dimension scores alongside were ranked from 1 to 100
across dimensions to identify the most problematic and
least problematic recommendations and dimensions.
All median scores were reasonably high on the overall
merit scale, ranging from 18 out of 25 (recommendation
#4) to 25 out of 25 (recommendation #10) (tabulated
scores not shown). The majority of top-ranked ethical
recommendations on overall merit were care-related, in-
cluding, Trial participants should get access to optimal
care and treatment for HIV infection, including ART
(recommendation #11). The majority of bottom-ranked
ethical recommendations on overall merit were preven-
tion-related, including, Trial participants should get access
to all state of the art HIV prevention services (recommen-
dation #1). The highest ranked recommendations on over-
all merit were both informed consent recommendations,
namely recommendation #10, In the informed consent
process, trial participants should be told what prevention
services they will receive, and recommendation #17, In the
informed consent process, trial participants should be told
what care and treatment services they will receive. The five
lowest ranked recommendations were all prevention-re-
lated: The protocol should describe how stakeholders will
negotiate adding new methods to the risk reduction pack-
age (recommendation #4), New prevention methods should
be added to the prevention package based on consultation
among all stakeholders (recommendation #3), Stakeholders
should discuss disseminating results about how the
standard of prevention was implemented in the trial
(recommendation #8), New prevention methods should be
added to the prevention package as they are validated orapproved by relevant authorities (recommendation #2),
and Trial participants should get access to all state of the
art HIV prevention services (recommendation #1).
Dimension scores for ethical recommendations
The five dimension scores for each ethical recommenda-
tion were also ranked and these rankings are presented in
Figure 1. Overwhelmingly, the dimension that ranked low-
est across recommendations was “Ease of Implementing”.
Indeed, for every single recommendation, “Ease of imple-
menting” was the lowest ranked of the five dimension
scores. Conversely, the dimension that ranked highest
across recommendations was “Agreement with”. For all
five most challenging recommendations, scores for the
“Agreement with” dimension had higher ranks than the
other four dimensions. In fact, “Agreement with” for
recommendation #2 and recommendation #1 were in
the top quarter of 100 possible dimension rankings
despite the problematic ratings on other dimensions
for these recommendations.
The bottom-ranked recommendation under each dimen-
sion was identified to clarify which recommendations were
most problematic in each dimension. The recommenda-
tion that was most problematic in terms of “Familiarity
with”, “Ease of Implementing”, and “Perceived Protection”
was recommendation #4, The protocol should describe how
stakeholders will negotiate adding new methods to the risk
reduction package. Most problematic in terms of “Ease of
Understanding”, was recommendation #2, New prevention
methods should be added to the prevention package as they
are validated or approved by relevant authorities and most
problematic for “Agreement with” was recommendation
#3, New prevention methods should be added to the preven-
tion package based on consultation among all stakeholders.
Prevention versus care recommendations
The second question driving this study was, do stakeholders
perceive care recommendations to be more or less chal-
lenging than prevention recommendations? Care recom-
mendations were scored higher overall than prevention
recommendations. (p = 0.002). Care recommendations were
also scored higher for the dimensions “Familiarity with”
(p = 0.004), “Ease of Understanding” (p = 0.010), “Per-
ceived Protection” (p = 0.969) and “Ease of Implementing”
(p < 0.001). After adjusting for multiple testing, differences
in median score between care and prevention recommen-
dations were considered significant (p = 0.003) overall, and
for the dimensions “Ease of Implementing” and “Perceived
Protection”.
The study’s third question was what differences exist be-
tween stakeholder groups (if any) regarding their views on
ethical recommendations? For prevention recommenda-
tions there was a significant difference in views among the
three stakeholder groups for the “Ease of Implementing”
Figure 1 (See legend on next page.)
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Figure 1 Recommendations ranked from top to bottom scores and dimensions ranked from top to bottom scores. This table shows the
ethical recommendations in order from the most positive global rating (1) to the least positive global rating (20). Each ethical recommendation
was rated by participants on “Ease of Implementing”, “Perceived Protection”, “Ease of Understanding”, “Familiarity with”, and “Agreement with”.
For each ethical recommendation, we worked out the average score for each dimension. Since there were 20 statements that were each ranked
on five dimensions, there were 100 scores in total. We ranked these in order from 1 (the highest scoring recommendation-dimension score) to
100 (the lowest scoring recommendation-dimension score). We used green shading to highlight the highest rankings, orange to represent the
middle-rankings, and red to highlight the lowest rankings.
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mensions. For care recommendations there was also a
significant difference in views between the three stake-
holder groups for the “Ease of Implementing” (p < 0.001)
and “Perceived Protection” (p = 0.002). The REC group
assigned noticeably lower scores across recommendations
and dimensions when compared to the other two
stakeholder groups.
Discussion
Overall merit of ethical recommendations
The findings indicate that both care and prevention rec-
ommendations were rated favourably overall. This result
reflects well on the international guidelines as it suggests
that these recommendations were viewed positively by
stakeholders operating at the coal-face of HVTs.
The prominence of informed consent recommendations
is not surprising. The high profile of consent requirements
in ethics discourse generally [53] and the presence of well
accepted mechanisms to implement consent requirements
(such as written forms) might explain the especially high
rankings for “Familiarity with” and “Ease of Understand-
ing” for recommendations that participants be informed
about the care or prevention efforts they will receive. High
level of agreement with these two informed consent
recommendations is consistent with the wide recognition
and popular acceptance of the principle of respect for
autonomy [54-56] and suggests that these stakeholders
agree that participants should be aware of the package on
offer as part of their overall participation [39,57]. A previ-
ous study also found that HVT stakeholders in South
Africa spontaneously identified 'informed consent' most
frequently as a critical issue for HVTs [46].
One of the highest-ranked ethical recommendations
was 'Trial participants should get access to optimal care
and treatment for HIV infection, including ART' (recom-
mendation #11). The high dimension rank for “Perceived
Protection” (6/100) by this recommendation suggests
that South African stakeholders are fairly unified in the
view that high quality HIV care protects participant
rights and promotes their welfare. It is not clear whether
respondents index ‘optimal’ to international or national
standards, but appear to endorse access to an antiretro-
viral regimen as a core protection. “Familiarity with”
ranked high for this recommendation (4/100) which isexplained by the high-profile debate about ART-access
in such trials [7,23,58].
The findings show that most top ranked recommen-
dations on overall merit were care-related and bottom
ranked recommendations were prevention-related. As
alluded to above, higher scores assigned to care rec-
ommendations might be explained by years of deliber-
ation - and emergent consensus, as some claim [59]
about sponsor-investigators' responsibilities to ensure ac-
cess to ART. Increased access to such treatment facilitated
by national governmental programs as well as donor-
funded initiatives [60] and the emergence of collabora-
tions to meet such responsibilities could also explain the
higher scores assigned to care recommendations. Con-
versely, participant access to effective preventive methods
are likely to reflect a more recent, contemporary and
pressing controversy for stakeholders, given the latest
successes of prevention products in trials such as PrEP
[61] and microbicides [62]. While the issue of adding new
methods to prevention packages did feature in early
papers on HVTs [7] it is recent successes in biomedical
prevention trials that have brought this debate to promi-
nence [19]. There is arguably less consensus on how
recent results should be translated into standards of
prevention in trials than there is for access to ART.
Care versus prevention recommendations
A close read of the dimension scores indicated that low
scores assigned to “Ease of Implementing” contributed
substantially to the pattern of lower ranking for preven-
tion recommendations. It is worth noting that “Agreement
with” was ordered high in the dimension rankings with
each of the bottom 5 recommendations; and “Agreement
with” was even positioned decently when ranked against
all other dimensions for all recommendations. This finding
suggests that respondents agreed with these recommenda-
tions- all five of which are prevention-related- but viewed
them as difficult to apply in practice, suggesting that the
solution may be to provide more help in how to realize the
standards in practice. This finding intersects somewhat
with the observation that merely because an ethical
standard is difficult to attain does not render the standard
wrong [63].
One possible explanation for low ranking on “Ease of
Implementing” and low to moderate ranking on “Ease of
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respondents may struggle to operationalise broad concepts
contained therein, such as ‘validation’ (recommendation
#2), ‘approval by relevant authorities’ (recommendation
#2), and 'state of the art' (recommendation #1). It suggests
that stakeholders need more refined or elaborated guidance
to help them to implement these recommendations or to
realize them in practice, which is a point we will
return to under ‘conclusions and recommendations’.
The 3 bottom-ranked recommendations out of 20 are
all concerned with inter-stakeholder engagement acti-
vities regarding prevention, therefore it is possible that
respondents may anticipate tensions between stake-
holders regarding standards of prevention when trying
to 'negotiate' (recommendation #4), 'consult' (recom-
mendation #3), and 'discuss' (recommendation #8). This
conclusion is supported by significant inter-stakeholder
differences (see below).
Most problematic recommendations by dimensions
Recommendation #4 [The protocol should describe how
stakeholders will negotiate adding new methods to the risk
reduction package] was the lowest recommendation for
the following dimensions - “Familiarity with”, “Perceived
Protection” and “Ease of Implementing”. The contribution
of these bottom dimension scores to recommendation
#4’s overall bottom rank (out of 20) suggests it requires
more careful thought and reformulation. It is not clear
whether these stakeholders were questioning the overall
approach inherent in ‘moral negotiation’ about prevention-
related benefits as set out by ethical commentators [64] or
whether they were questioning the value of committing to
paper plans in this regard because of reservations about
preserving flexible innovative responses to participants'
prevention needs [57].
Recommendation #2 [New prevention methods should be
added to the prevention package as they are validated or
approved by relevant authorities] was the bottom recom-
mendation under “Ease of Understanding”. As mentioned
earlier, more substantive elaboration in the ethical guidance
might help stakeholders to understand key concepts such
as ‘validation’ (e.g. what threshold of evidence?) and
‘approval’ (e.g. which agencies?) which is a point we will
return to under ‘conclusions and recommendations’.
Recommendation #3 [New prevention methods should
be added to the prevention package based on consultation
among all stakeholders] was the bottom-ranked recom-
mendation under “Agreement with” (64/100) even while
“Agreement with” was a high-ranked dimension generally.
While respondents did not disagree, they did not indicate
overwhelming support for this recommendation. This
indicates that these stakeholders may not share the
view that all stakeholders should be consulted about
this issue, reflecting a possible skepticism about throwingthe net too wide for consultation which might delay a
timely decision.Stakeholder differences
Significant differences were found between stakeholder
groups on “Ease of Implementing” and “Perceived Protec-
tion” for both prevention recommendations combined
and care recommendations combined, with significantly
lower scores for the REC stakeholder group. This suggests
that specific stakeholder groups hold different views about
whether certain recommendations can protect trial partic-
ipants in the first place, or whether recommendations
could ever be implemented in practice. This finding adds
a layer of detail to the long-recognized problem that
stakeholder consensus about critical components of trials
is difficult to achieve [13] and provides some clues about
why inter-stakeholder forums to debate such concerns
may break down or be marred by disagreement. Prior
reflection on difficulties in achieving consensus have
centered on inadequate negotiating power held by
community stakeholders [65]. This finding may be an
important topic for future research because current
ethical guidance recommends collective decision- making
across stakeholder groups [51] prior to trial commence-
ment regarding prevention and care.Limitations
It was a challenge to achieve a representative sample.
Response rates were low, especially within the site-staff
group (11%). The sampling methods needed to access
the target stakeholder groups eliminated the possibility
of random sampling, and instead participants self-selected
in response to questionnaire outreach. Given the small
population sizes, small samples and non-random sampling,
the perspectives of eligible stakeholders not included in the
sample remain unknown, and may differ from those of
study respondents. The study was also regionally specific.
Only South African HVT stakeholders were sampled.
For these reasons, inference to a larger population of
stakeholders is not made from these findings.
Certain stakeholder groups for HVTs were not sam-
pled for this study: sponsors, regulators and HVT parti-
cipants. Sponsors and regulators were excluded due to
the anticipated small numbers; the study team was inter-
ested in inter-stakeholder analysis and anticipated not
being able to recruit the sample size required to com-
pare such perspectives to other groups. HVT partici-
pants were not recruited because of the possible impact
on ongoing trials, and because of anticipated burden in
securing permissions necessary to access participants.
However, further research on HVT stakeholder perspec-
tives would benefit from inclusion of these stakeholder
groups.
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to exploring the adequacy of ethical recommendations,
whereas some might argue that conceptual analysis is a
better approach. However, empirically describing the
views of vaccine stakeholders about the merit of various
recommendations arguably provides a platform from which
to consider how to make guidance potentially more
helpful and implementable.
During the study, the GPP guidelines (2007) were
superseded by a new edition [51], which excluded the
recommendations listed as #6 and #8, however the
others are still relevant. In 2012, a new point was added
to the UNAIDS guidelines on Participants who use Intra-
venous Drugs resulting in a re-release [52] which does not
affect the relevance of these questionnaire items.
Conclusions and recommendations
All recommendations related to prevention and care
were rated favourably by our respondents in terms of
overall merit which indicated that they are perceived as
helpful by core role-players. Care recommendations
were rated more favourably than prevention recommen-
dations, therefore we propose that prevention recom-
mendations be prioritized for refinement by guideline
drafters, especially those assigned bottom-ranking scores
for “Ease of Implementing”, and/or “Ease of Understan-
ding” in order to assist vaccine stakeholders to better
comprehend and implement these recommendations.
Based on findings about which dimensions drive lower
scores assigned to prevention recommendations, we
recommend some elaboration in guidance of the broad
concepts to enable stakeholders to better understand and
implement prevention recommendations. Such broad con-
cepts include ‘validation’, ‘consultation of all stakeholders’
and ‘approval by authorities’. It is likely that vaccine stake-
holders will need more operational guidance on specific
issues such as establishing the safety (including combi-
nation effects) of the prevention modality for the trial
population, establishing clinical benefit of the prevention
modality for the trial population [66], determining which
role-players in the national context are to be selected for
consultation, which activities constitute appropriate
‘consultation’, and which consultative formats (e.g. meet-
ings, protocol reviews) are appropriate. Further qualitative
research could also assist to better understand nuances in
stakeholder reservations about implementing such recom-
mendations for HVTs, which could be used to better
translate broad recommendations into effective practice.Additional file
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